PharmaMar reports positive results for Aplidin® against coronavirus HCoV-229E

- These studies have been carried out at the National Biotechnology Centre (Centro Nacional de Biotecnología) of the Spanish National Research Council (CSIC).
- PharmaMar will contact regulatory authorities to analyze the possibilities of studies on patients infected with Covid-19.

Madrid, March 13th, 2020. PharmaMar (MSE:PHM) reports that the in vitro studies results of Aplidin® (plitidepsin) on the human coronavirus HCoV-229E, which has a multiplication and propagation mechanism very similar to Covid-19, have been positive with a potency of the nanomolar order. These studies have been carried out at the National Biotechnology Centre (Centro Nacional de Biotecnología) of the Spanish National Research Council (CSIC) by Dr Luis Enjuanes, Dr Isabel Solá and Dr Sonia Zúñiga.

These results confirm the hypothesis that the therapeutic target of Aplidin® (plitidepsin), which is EF1A, is key to the multiplication and spread of the virus.

With these data, PharmaMar will contact regulatory authorities to analyze the possibilities of studies on patients infected with Covid-19.

Legal warning
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar
Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.
Media Contact:
Alfonso Ortín – Communications Director aortion@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000

Capital Markets & Investor Relations:
José Luis Moreno – Director investorrelations@pharmamar.com
Phone: +34 914444500

Or please visit our website at www.pharmamar.com